Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 676 - 700 of 11606 in total
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann...
Approved
Matched Description: … Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E ... After approval, Roche in collaboration with Genentech launched a broad development program. [L1012] …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated...
Approved
Investigational
Withdrawn
Matched Description: … a light chain linked by a disulfide bond. ... It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and ... Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective …
Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia. The approved application holder removed Merital capsules from the market on January 23, 1986. FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal...
Approved
Withdrawn
Matched Description: … FDA published a notice of its determination that Merital capsules were removed from the market for safety …
Approved
Experimental
Agalsidase beta is a recombinant human α-galactosidase A similar to agalsidase alfa. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Investigational
Matched Description: … Agalsidase beta is a recombinant human α-galactosidase A similar to [agalsidase alfa]. ... While patients generally do not experience a clinically significant difference in outcomes between the ... A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a
An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)
Approved
Tolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory agent. It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam. In the US, it presents a Status class I by the...
Approved
Investigational
Matched Description: … [L1292] In the US, it presents a Status class I by the FDA. ... It is used in the UK as a treatment for migraine under the name of Clotam. ... Tolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory …
Poa annua pollen is the pollen of the Poa annua plant. Poa annua pollen is mainly used in allergenic testing.
Approved
Iva annua pollen is the pollen of the Iva annua plant. Iva annua pollen is mainly used in allergenic testing.
Approved
Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to Bacillus anthracis. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis...
Approved
Matched Description: … [L47526] It is considered one of the most likely agents to be used in a biological attack. ... Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high ... microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a
Viper antivenom consists of antibodies derived from horses immunized and subsequently developed antibodies against snake venoms. ANAVIP, an equine-derived antivenom made with venom from Bothrops asper and Crotalus durissus, was first approved by the FDA on October 1, 2015, for the management of North American rattlesnake envenomation.
Approved
Approved
Investigational
Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to neridronic acid and alendronic acid. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as ibandronic acid, zoledronic acid, minodronic acid, and risedronic acid are becoming...
Approved
Matched Description: … Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid …
Amylmetacresol is an antiseptic available in Canada over-the-counter in a number of lozenges for the treatment of sore throat and minor mouth infections , . Amylmetacresol is often combined with dichlorobenzyl alcohol and menthol in the commonly used sore throat lozenges, known as Strepsils . The acute sore throat (pharyngitis)...
Approved
Matched Description: … Amylmetacresol is an antiseptic available in Canada over-the-counter in a number of lozenges for the …
Moroctocog alfa, also known as BDDrFVIII (B domain deleted recombinant factor VIII), is a recombinant DNA-based drug with functional characteristics comparable to those of endogenous coagulation Factor VIII, the essential human blood clotting protein that is impaired in Hemophilia A. Moroctocog alfa is identical in sequence to endogenously produced Factor...
Approved
Matched Description: … Moroctocog alfa, also known as BDDrFVIII (B domain deleted recombinant factor VIII), is a recombinant ... in the Factor VIII gene, leading to a functional deficiency or complete loss of protein. ... coagulation Factor VIII, the essential human blood clotting protein that is impaired in Hemophilia A. …
Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. It was once available under the tradename Tral marketed by Abbvie Inc. but has been discontinued. Proton pump inhibitors like DB00338 and opiate anti-diarrheal agents like DB00836 have largely replaced the...
Approved
Matched Description: … Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment …
Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.[L7634,L7637,L7640,L7643,L8519] Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.[L7640,L7643] Glucagon was granted FDA...
Approved
Matched Description: … Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit …
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Approved
Matched Description: … Lennox-Gastuat syndrome, a form of childhood epilepsy. ... Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like …
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
Approved
Matched Description: … kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a
Matched Categories: … Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has...
Approved
Matched Description: … Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome) ... It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis infections.[L44592,L44597] Sulconazole appears to be effective...
Approved
Matched Description: … Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream …
Rezafungin is an echinocandin antifungal drug.[A258393,L45633] Unlike other echinocandins such as caspofungin and micafungin, rezafungin has long‐acting pharmacokinetics and a high stability that allows for it to have long dosing intervals maintaining high plasma exposure. Rezafungin has a half-life higher than 130 hours and can be administered once a week...
Approved
Investigational
Matched Description: … Rezafungin has a half-life higher than 130 hours and can be administered once a week instead of daily ... echinocandins such as [caspofungin] and [micafungin], rezafungin has long‐acting pharmacokinetics and a
Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Approved
Matched Description: … Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic …
Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions in the intestine . It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and for preparation of the colon for surgical procedures.
Approved
Matched Description: … Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions …
Haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is an active immunization as a booster dose given intramuscularly to pediatric patients who have received a primary series with a Haemophilus b Conjugate Vaccine that is licensed for primarly immunization. The vaccine contains Haemophilus b capsular polysaccharide...
Approved
Investigational
Matched Description: … booster dose given intramuscularly to pediatric patients who have received a primary series with a Haemophilus ... strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is an active immunization as a ... vaccine contains Haemophilus b capsular polysaccharide (polyribosyl-ribitol-phosphate [PRP]), which is a
Displaying drugs 676 - 700 of 11606 in total